🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

91 results for “Bristol-Myers Squibb / Pfizer EEIG” Clear

  1. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  2. KarXT, KarXT, KarXT, Karxt Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  3. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb / Pfizer EEIG

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  4. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb / Pfizer EEIG

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  5. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  6. MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL

    Bristol-Myers Squibb / Pfizer EEIG

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  7. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  8. Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  10. OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  11. OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  12. OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, BNT327 20 mg ml, CAPECITABINE, BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BNT327 50 mg ml, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  13. Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl 0.23 mg , Ozanimod HCl 1 mg , Ozanimod HCl 0.0575 mg , Ozanimod HCl 0.25 mg, Fingolimod 0.25 mg capsule, Fingolimod 0.5 mg capsule

    Bristol-Myers Squibb / Pfizer EEIG

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. Ozanimod, Ozanimod, Ozanimod

    Bristol-Myers Squibb / Pfizer EEIG

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  15. PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb / Pfizer EEIG

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  18. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  19. Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  20. XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Bristol-Myers Squibb / Pfizer EEIG

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  21. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  22. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  23. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  24. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb / Pfizer EEIG

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources